Keywords: actelion, unveils, new, pipeline, targets, first, day
Actelion unveils new pipeline targets in first R&D Day presentation
Article | 10 June 2002
Extending the indications for Tracleer (bosentan) and developing Veletri(tezosentan) for acute heart failure are the two key near-term priorities ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Aspen Pharma offers to buy GlaxoSmithKline's thrombosis brands and manufacturing site
- US Supreme Court says patent settlement can "sometimes" be illegal
- Athera and Boehringer Ingelheim enter option agreement on a novel therapy for atherosclerosis
- FDA probes two deaths possibly linked to Lilly's antipsychotic Zyprexa Relprevv
- Australia's pharma industry applauds R&D regulatory reform
